ĐĎॹá>ţ˙ ‰‹ţ˙˙˙‡ˆ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ěĽÁ7 đżTQbjbjUU &ž7|7|TL˙˙˙˙˙˙l¨¨¨¨¨¨¨źHHHH TtźC*śÔÔÔÔÔÔÔÔŞ)Ź)Ź)Ź)Ź)Ź)Ź)$ů* -ŚĐ)-¨ÔÔÔÔÔĐ)@)¨¨ÔÔý)@)@)@)Ô2¨Ô¨ÔŞ)@)ÔŞ)@)j@)Ş)¨¨Ş)ÔČ ˝IjŢĆźŒH : Ş)Ş)*0C*Ş)ż-@)ż-Ş)@)źź¨¨¨¨Ů VITAL INFO - Alternative TB TEST! (blood test) ASK FOR THIS TEST instead of getting the PPD or other TB test! (PPD has TB in it and can be just as dangerous as a vaccine - I know several children who regressed back into autism after receiving a TB test) From one of my students..... "They just draw a tube of blood, which I have no problem with. No ppd. I've got an email in to my Kaiser dr. asking for this. If they don't do it or the cost is prohibitive, the SF health dept. does it for $13" Sheri http://www.medscape.com/viewarticle/520274 * The QFT-G should be used in all settings in which the TST is currently used, including contact investigations, evaluation of recent immigrants with BCG vaccination, and TB screening of healthcare providers. * Advantages of the QFT-G vs the TST include specificity for individuals with a history of BCG vaccine and convenience of administration. Data on the sensitivity of the QFT-G for children, immunocompromised individuals, and its ability to predict disease progression are needed. http://lungdiseases.about.com/od/testingdiagn4/a/quantiferon_tb.htm Tuberculosis Testing - What is the QuantiFERON-TB Test? From Stacey Lloyd,Your Guide to Lung Diseases. Tuberculosis Testing Choices In 2001, the Food and Drug Administration (FDA) approved the tuberculosis test called QuantiFERON-TB (QFT). This tuberculosis test measures the release of interferon-gamma (IFN-g) in whole blood in response to stimulation of the purified protein derivative from M. tuberculosis. In laymen's terms, the QFT tuberculosis test measures a person's immune reactivity to Mycobacterium tuberculosis, the bacterium that causes tuberculosis. How Does the QFT Tuberculosis Test Work? A blood sample is drawn from the patient. The blood is mixed with antigens - the protein substances that produce an immune response - and controls. The antigens include tuberculin, which is purified protein derivative (PPD) from M. tuberculosis, and avian sensitin, which is purified protein derivative from My avium complex. Then the blood is incubated for 16 to 24 hours. At the end of the incubation period, the QFT tuberculosis test is read. If the patient tests positive for tuberculosis, i.e. the patient is infected with M. tuberculosis, the blood cells would have released a larger proportion of IFN-g in response to the tuberculin than that released in response to the avian sensitin or the controls. However, in order to confirm or exclude a tuberculosis diagnosis, additional testing, such as a chest x-ray, is required. (Read What You Need to Know Before Getting A Chest X-Ray) Advantages of QFT Tuberculosis Test # Only one doctor visit is required # The test assesses responses to multiple antigens simultaneously # Eliminates the concern of the booster phenomenon as seen with the PPD tuberculosis skin test # Reduced risk of testing interpretation errors and bias Disadvantages of QFT Tuberculosis Test # Time limit (12 hours) for testing of the drawn blood # Limited knowledge and experience with QFT tuberculosis test # The QFT's ability to predict the progression of tuberculosis infection to tuberculosis disease has not been evaluated # Additional testing required to confirm or exclude tuberculosis diagnosis Source: CDC *********** http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250103.htm Fact Sheets Return to Fact Sheets Main Menu PDF QuantiFERONŽ-TB Gold Test What is it? The QuantiFERONŽ-TB Gold test (QFT-G) is a whole-blood test for use as an aid in diagnosing Mycobacterium tuberculosis infection, including latent tuberculosis infection (LTBI) and tuberculosis (TB) disease. This test was approved by the U.S. Food and Drug Administration (FDA) in 2005. How does it work? Blood samples are mixed with antigens (substances that can produce an immune response) and controls. For QFT-G, the antigens include mixtures of synthetic peptides representing two M. tuberculosis proteins, ESAT-6 and CFP-10. After incubation of the blood with antigens for 16 to 24 hours, the amount of interferon-gamma (IFN-gamma) is measured. If the patient is infected with M. tuberculosis, their white blood cells will release IFN-gamma in response to contact with the TB antigens. The QFT-G results are based on the amount of IFN-gamma that is released in response to the antigens. Clinical evaluation and additional tests (such as a chest radiograph, sputum smear, and culture) are needed to confirm the diagnosis of LTBI or TB disease. What are the advantages? * Requires a single patient visit to draw a blood sample. * Results can be available within 24 hours. * Does not boost responses measured by subsequent tests, which can happen with tuberculin skin tests (TST). * Is not subject to reader bias that can occur with TST. * Is not affected by prior BCG (bacille Calmette-Guérin) vaccination. What are the disadvantages and limitations? * Blood samples must be processed within 12 hours after collection while white blood cells are still viable. * There are limited data on the use of QFT-G in children younger than 17 years of age, among persons recently exposed to M. tuberculosis, and in immunocompromised persons (e.g., impaired immune function caused by HIV infection or acquired immunodeficiency syndrome [AIDS], current treatment with immunosuppressive drugs, selected hematological disorders, specific malignancies, diabetes, silicosis, and chronic renal failure). * Errors in collecting or transporting blood specimens or in running and interpreting the assay can decrease the accuracy of QFT-G. * Limited data on the use of QFT-G to determine who is at risk for developing TB disease. When should you use the test? QFT-G can be used in all circumstances in which the tuberculin skin test (TST) is currently used, including contact investigations, evaluation of recent immigrants who have had BCG vaccination, and TB screening of health care workers and others undergoing serial evaluation for M. tuberculosis. However, caution should be used when testing certain populations because of limited data in the use of QFT-G. Before the QFT-G is conducted, arrangements should be made with a qualified laboratory and courier service, if needed, to ensure prompt and proper processing of blood. What are the steps in administering the test? * Confirm arrangements for testing in a qualified laboratory and arrange for delivery of the blood sample in time for the laboratory to initiate testing within 12 hours of blood collection. * Draw a sample of whole blood from patient into a tube with heparin anti-clotting agent, according to manufacturer’s instructions. * Schedule an appointment for the patient to receive test results and, if then needed, medical evaluation and possible treatment for TB disease or LTBI. How do you interpret test results? Interpretation of QFT-G results is based on IFN-gamma concentrations in test samples. Each QFT-G result and its interpretation should be considered in conjunction with other epidemiological, historical, physical, and diagnostic findings. A positive result suggests that M. tuberculosis infection is likely; a negative result suggests that infection is unlikely; and indeterminate result suggests QFT-G results cannot be interpreted as a result of low mitogen response or high background response. A diagnosis of LTBI requires that TB disease be excluded by medical evaluation, which should include checking for signs and symptoms suggestive of TB disease, a chest radiograph, and, when indicated, examination of sputum or other clinical samples for the presence of M. tuberculosis. Additional Information Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis and Guidelines for using the QuantiFERONŽ-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005; 54 (No. RR-15). http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf (PDF) Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005. MMWR 2005; 54 (No.RR-17). http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf (PDF) Back to Top of Page You will need Adobe Acrobat"! Reader v3.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat"! Reader. If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available. Division of Tuberculosis Elimination Attn: Content Manager, DTBE Web site Centers for Disease Control and Prevention 1600 Clifton Rd., NE Mailstop E-10 Atlanta, GA 30333 (404) 639-8135 E-mail: cdcinfo@cdc.gov ********** http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ui ds=15729888&dopt=Abstract 1: Kekkaku. 2004 Nov;79(11):637-43. Related Articles, Links [Usefulness of a novel diagnostic method of tuberculosis infection, QuantiFERON TB-2G, in an outbreak of tuberculosis] [Article in Japanese] Harada N, Mori T, Shishido S, Higuchi K, Sekiya Y. Immunology Division, Research Institute of Tuberculosis, JATA, Tokyo, Japan. harada@jata.or.jp OBJECTIVE: The purpose of this study was to evaluate QuantiFERON TB-2G (QFT), a novel method of detecting tuberculosis infection among contacts of a tuberculosis patient by determining the whole-blood interferongamma response to the specific antigens. SUBJECTS AND METHODS: A teacher of a college who had been coughing for the preceding two months was diagnosed with smear-positive tuberculosis. About 270 students of the college were considered to have been exposed to tuberculosis infection, of whom 73 were in closer contact with the index case because they participated in a one-week group excursion attended by the teacher. Two of the contact students developed active tuberculosis shortly thereafter. Tuberculin tests were conducted to almost all students, and QFT was performed for only those with tuberculin reactions having erythema diameters of 30 mm or larger. RESULTS: Tuberculin tests of students, all of whom had been vaccinated with BCG at least once, revealed that the distribution of the close contact group was slightly shifted to right (larger side) than those with less close contacts. The QFT positive rate for close contacts was 45.5%, while that for less close contacts was only 7.1%, which obviously indicates that QFT is hardly affected by the tuberculin allergy due to past BCG vaccination. The distribution of interferon-gamma measurements (log-transformed) of the close contacts showed typical bimodality, one mode representing the infected, another the non-infected. This was not clear for the less close contacts. The correlation of interferon-gamma measurements (log-transformed) with tuberculin reaction erythema size was weak, if not non-significant. CONCLUSION: It was concluded that QFT was a useful method for diagnosing tuberculosis infection and was unaffected by the BCG-caused tuberculin allergy. In the case of the outbreak mentioned above, QFT greatly reduced the indication of chemoprophylaxis, from 28% of all the contacts solely based on tuberculin test to only 7%. Although there remains some problems to be overcome for QFT to be widely used with high confidence, this technology will provide a high possibility for wider and more accurate indication of chemoprophylaxis and will be one of the essential tools of tuberculosis control of the 21st century in Japan. PMID: 15729888 [PubMed - indexed for MEDLINE] *********** http://www.medscape.com/viewarticle/520274 CDC Issues Guidelines on Use of QuantiFERON TB Gold Test CME News Author: Laurie Barclay, MD Dec. 22, 2005 — The QuantiFERON TB Gold test (QFT-G) essentially can be used in all cases in which the tuberculosis skin test is currently used, according to new guidelines released by the US Centers for Disease Control and Prevention (CDC) and published in the Dec. 16 issue of the Morbidity and Mortality Weekly Report: Recommendations and Reports. These guidelines are intended for public health officials, healthcare providers, and laboratory workers with responsibility for TB control activities in the United States. "On May 2, 2005, a new in vitro test, QuantiFERON-TB Gold (QFT-G, Cellestis Limited, Carnegie, Victoria, Australia), received final approval from the U.S. Food and Drug Administration (FDA) as an aid for diagnosing Mycobacterium tuberculosis infection," write Gerald H. Mazurek, MD, and colleagues from the Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention. "This test detects the release of interferon-gamma (IFN-?) in fresh heparinized whole blood from sensitized persons when it is incubated with mixtures of synthetic peptides representing two proteins present in M. tuberculosis: early secretory antigenic target–6 (ESAT-6) and culture filtrate protein–10 (CFP-10). These antigens impart greater specificity than is possible with tests using purified protein derivative [PPD] as the tuberculosis (TB) antigen." Direct comparisons have shown that the sensitivity of QFT-G was not statistically different from that of the tuberculin skin test (TST) for detecting infection in people with untreated culture-confirmed TB. Currently, the diagnostic value of QFT-G for finding latent TB infection (LTBI) is being evaluated in certain populations targeted by TB control programs in the United States. To date, the ability of this test to predict who will eventually have TB disease is unknown, and years of observational research in large cohorts would be needed to determine this. In July 2005, the CDC organized a meeting of experts to review scientific evidence and clinical experience with QFT-G. This group concluded that QFT-G may be used in all circumstances in which the TST is now used, including contact investigations, evaluation of recent immigrants, and sequential-testing surveillance programs for infection control, such as those for healthcare workers. The CDC guidelines also list specific cautions for interpreting negative QFT-G results in selected subgroups populations and provide interim guidance for use and interpretation of QFT-G. "Confirming or excluding TB disease and assessing the probability of LTBI require a combination of epidemiologic, historic, physical, and diagnostic findings that should be considered when interpreting QFT-G results," the authors write. "This report is intended to assist public health officials, clinicians, and laboratorians in their efforts to understand the use of QFT-G for TB control." The FDA approved QFT-G as an in vitro laboratory test to assist in the diagnosis of both TB disease and LTBI, both in clinical and in public health settings, ideally in concert with the local or regional public health TB control program. Instructions for the QFT-G assay are in the package insert, and QFT-G test results can be calculated by using software provided by the manufacturer. The guidelines also include a table for interpreting test results. Laboratory reports should include interpretation of QFT-G test results and indicate the concentration of IFN-? in each plasma sample. Although some limitations of QFT-G appear to be similar to those of the TST, they have not been studied extensively to date. In persons with untreated, culture-confirmed TB, the sensitivity of QFT-G for detecting M. tuberculosis infection is approximately 80% in published studies, but the sensitivity in specific subgroups of TB patients, such as young children and immunocompromised patients, is still unknown. For LTBI, QFT-G sensitivity might be less than that of the TST, but the lack of a confirmatory test makes this difficult to evaluate. Estimating the sensitivity of any indirect test for LTBI by testing patients with TB disease might be inaccurate because of differences between these conditions, and the ability of QFT-G to predict risk for LTBI progressing to TB disease is still undetermined. Like the TST, QFT-G cannot distinguish infection associated with TB disease from LTBI. For definitive diagnosis of LTBI, TB disease must be ruled out by medical evaluation, which should include ascertaining history of suggestive symptoms and signs, chest x-ray, and examination of sputum or other clinical samples for M. tuberculosis when indicated. As for other diagnostic tests, the prevalence of M. tuberculosis infection in the population being tested affects the predictive value of QFT-G results. "Each QFT-G result and its interpretation should be considered in conjunction with other epidemiologic, historic, physical, and diagnostic findings," the guidelines note. "As with a negative TST result, negative QFT-G results should not be used alone to exclude M. tuberculosis infection in persons with symptoms or signs suggestive of TB disease. The presence of symptoms or signs suggestive of TB disease increases the likelihood that M. tuberculosis infection is present, and these circumstances decrease the predictive value of a negative QFT-G or TST result." Symptomatic individuals should have a medical evaluation including history and physical examination, chest x-ray, bacteriologic studies, serology for HIV, and other tests as indicated. The sensitivity and rate of indeterminate results using QFT-G has not been determined in immunocompromised persons with HIV infection, AIDS, current treatment with immunosuppressive drugs, selected hematologic disorders, and certain malignancies. These conditions or treatments are known or suspected to decrease responsiveness to the TST, and they might also decrease production of IFN-? in the QFT-G assay. As with a negative TST result, negative QFT-G results alone might be insufficient to exclude M. tuberculosis infection in these persons. Practical limitations of the QFT-G include the need for venipuncture and for transporting the 5-mL blood sample to a qualified laboratory in time for testing. "QFT-G can be used in all circumstances in which the TST is used, including contact investigations, evaluation of recent immigrants who have had BCG [Bacille Calmette-Guérin] vaccination, and TB screening of health-care workers and others undergoing serial evaluation for M. tuberculosis infection," the authors write. "QFT-G usually can be used in place of (and not in addition to) the TST. A positive QFT-G result should prompt the same public health and medical interventions as a positive TST result." The guidelines note that there is no reason to follow a positive QFT-G result with a TST; instead, those with a positive QFT-G result, regardless of their symptoms or findings, should be evaluated for TB disease before LTBI is diagnosed. HIV counseling, testing, and referral is also recommended because HIV infection increases the suspicion for TB and the urgency for treating LTBI. Once TB has been ruled out, treatment of LTBI should be considered. "For persons with recent contact with persons who have infectious TB, negative QFT-G results should be confirmed with a repeat test performed 8 - 10 weeks after the end of exposure, as is recommended for a negative TST result," the authors conclude. "Studies to determine the best time to retest contacts with negative QFT-G results have not been reported. Until more information is available, the timing of QFT-G testing should be the same as that used for the TST." MMWR Morb Mortal Wkly Rep. 2005;54(RR- 15):49-55 TQ01}Çk´Îóôúű&i°ű<yźţ^ýýýýýýýýýýýýýýýýýýýýýýýýýýýýýTQý^_—˜Çä. t ś ţ C ‡ • – ż S Ÿ ă . 5 6  Ë  V › ć -:ýýýýýýýýýýýýýýýýýýýýýýýýýýýýý:;_ƒĹ $]^…źúFr˝žĘÖ>B\hiłüGˆšýýýýýýýýýýýýýýýýýýýýýýýýýýýýýš›á,uÁőö?‡Îčé/y…žŸÝ T}ş12yŁíýýýýýýýýýýýýýýýýýýýýýýýýýýýýýí8€ĘR›Ú!89WXĄę5Ëíî:–ÄĹ Q‡ĐýýýýýýýýýýýýýýýýýýýýýýýýýýýýýZŚŹ­ĐŃeŞżŔ N • Ă Ä !T!›!á!ř!ů!8"~"ż"ů"#?#@#ýýýýýýýýýýýýýýýýýýýýýýýýýýýýý@#Š#Ô#î#<$D$F$J$L$t$v$ %r%t%&P&&‚&§&Ě&÷&',';'S'T'_'Ź'Ć'(ýýýýýýýýýýýýýýýýýýýýýýýýýýýýý((L((€(š(›(Ň(Ó()6)7)‚)Î)*\*Ľ*î*9+~+Ă+,[,Ł,ď,6-}-Ç-.S.ýýýýýýýýýýýýýýýýýýýýýýýýýýýýýS.’.Ţ.*/t/ž/ 0T0™0á0-1n1¸1ü1B2C2u2v2‚2­2ë2ě2 3 33V3Ÿ3ę334~4ýýýýýýýýýýýýýýýýýýýýýýýýýýýýý~4Â4 555f5°5ń596ƒ6Ć67Q7—7ă7)8n8o8ł8ű8>9‡9Ď9:f:Ł:¤:î:5;z;ýýýýýýýýýýýýýýýýýýýýýýýýýýýýýz;Á; <M<”<â<ă<-=x=Á= >T>k>l>ł>ů>??†?Ń?@c@Š@¸@š@AFA‘AŰA$BfBýýýýýýýýýýýýýýýýýýýýýýýýýýýýýfB¨BëB1CrCźCáCâC.DxDźDEME’EŮEÚEFeFŽFúFFG’GÚGHH[HŚHÉHĘHIýýýýýýýýýýýýýýýýýýýýýýýýýýýýýI_IŤI÷I;J‚JĂJěJíJ6KKŒKKŮK"LiL­LřLDM‡MˆMĎMNcN¤NíN6OLOMO“Oýýýýýýýýýýýýýýýýýýýýýýýýýýýýý“OßO(PnP¸PQ!Q"QSQTQýýýýýýýýý $&P1h°Đ/ °ŕ=!° "°Đ#Đ$Đ%° i8@ń˙8 NormalCJ_HaJmH sH tH <A@ň˙Ą< Default Paragraph FontTLž˙˙˙˙01}Çk´Îóôúű&i°ű<yźţ^_—˜Çä.tśţC‡•–ż SŸă.56Ë V › ć - 12yŁí8€ĘR›Ú!89WXĄę5Ëíî:–ÄĹ Q‡ĐZŚŹ­ĐŃeŞżŔN•ĂÄT›ářů8~żů?@ŠÔî " # % & : ; … š ş !P!!‚!§!Ě!÷!",";"S"T"_"Ź"Ć"##L##€#š#›#Ň#Ó#$6$7$‚$Î$%\%Ľ%î%9&~&Ă&'['Ł'ď'6(}(Ç()S)’)Ţ)**t*ž* +T+™+á+-,n,¸,ü,B-C-u-v-‚-­-ë-ě- . ..V.Ÿ.ę.3/~/Â/ 000f0°0ń091ƒ1Ć12Q2—2ă2)3n3o3ł3ű3>4‡4Ď45f5Ł5¤5î556z6Á6 7M7”7â7ă7-8x8Á8 9T9k9l9ł9ů9?:†:Ń:;c;Š;¸;š;<F<‘<Ű<$=f=¨=ë=1>r>ź>á>â>.?x?ź?@M@’@Ů@Ú@AeAŽAúAFB’BÚBCC[CŚCÉCĘCD_DŤD÷D;E‚EĂEěEíE6FFŒFFŮF"GiG­GřGDH‡HˆHĎHIcI¤IíI6JLJMJ“JßJ(KnK¸KL!L"LSLVL˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€š€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€TQO^:ší@#(S.~4z;fBI“OTQPRSTUVWXYZ[\]^TQQźÍ‚¤Ž:EżÇöűl t  B M m x Ţĺćő8I•œ—˘ ""Ź"Ž"É"Đ"L#W#ą#š#Č#Î#p${$%%|'„'Ÿ*§*ť+Ë+Ô,ä,W-]-Í-Ř-".-.@0K0\0e0(1/1č1ó12–2F8S89)9(=9=3A@A#D4DD›D%F1F#G*G+G:G'L+LVL$)}ÇĘkn´ˇÎŃir°ş<Gy‡źÍţ ŠŽ.2t{śÁţCM‡“ ŸŁăí.3„ËĎ  V ^ › ˘ ć ë  F R  Ľ ł ś ü GOáç,5ÁÇ?CÎÖ/5TZy~8I€‰ĘΛž!+ęđ59ËŇ:D‹ QYĐÔZ\egŞ´NT•œTV›Ąů$8E@kŠÓÔí… ‡ !!P!T!Œ""Ź"Ž"Ú"Ý"Î$Ď$%%\%c%Ľ%Š%î%ř%9&;&~&&Ă&Ë&''['_'6(;(}(‚(Ç(Ë(S)^)“)–)Ţ)ę)**-*u*x*ž*Á* + +T+^+™+ +á+é+-,1,n,x,¸,ź,ü,-á-ę-V.Z.Ÿ.¨.ę.í.3/6/~//Â/Ě/91C1ƒ1†1Ć1Đ122Q2]2—2 2ă2ë2)313ł3Ŕ3ű34Ď4×455f5n5î5ö5N6[6z6ƒ6Á6Ë6 77M7U7”7Ÿ7-848x8€8Á8Č8 99ł9ź9ů9˙9?:E:†::Ń:Ů:;#;c;e;Ą;Ł;Š;Ż;F<O<‘<<Ű<ć<$='=f=q=¨=´=ë=ö=1>8>r>|>ź>ž>.?2?x?z?ź?Ć?@ @M@W@’@œ@A'AeAmAúAüAFBNB’BžBÚBäB[C^CŚCČCDD_DhDŤD˛D÷DůD;EEEOEQE‚EŠEĂEĎE6F9FF‚FŮFŕFiGpG­GśGřGűGDHJHĎHŐHII¤IŻIíIôI6J †!đ Đ9´‚20JM2ƒđ˙˙ VITAL INFO - Alternative TB TESTValued CustomerValued Customerţ˙ŕ…ŸňůOhŤ‘+'łŮ0”˜ÄĐčô (4 P \ ht|„Œä!VITAL INFO - Alternative TB TESTrosITAValued CustomeralualuNormalCValued Customer1luMicrosoft Word 9.0a@FĂ#@žßËiŢĆ@ä˘ďiŢĆ đ>ţ˙ŐÍ՜.“—+,ůŽ0 hp|„Œ” œ¤Ź´ ź éä † JM  !VITAL INFO - Alternative TB TEST Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_ţ˙˙˙abcdefghijklmnopqrstuvţ˙˙˙xyz{|}~ţ˙˙˙€‚ƒ„…†ţ˙˙˙ý˙˙˙ý˙˙˙Šţ˙˙˙ţ˙˙˙ţ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙Root Entry˙˙˙˙˙˙˙˙ ŔFxNjŢĆŒ€1Table˙˙˙˙˙˙˙˙˙˙˙˙`ż-WordDocument˙˙˙˙˙˙˙˙&žSummaryInformation(˙˙˙˙wDocumentSummaryInformation8˙˙˙˙˙˙˙˙˙˙˙˙CompObj˙˙˙˙jObjectPool˙˙˙˙˙˙˙˙˙˙˙˙xNjŢĆxNjŢĆ˙˙˙˙˙˙˙˙˙˙˙˙ţ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ţ˙ ˙˙˙˙ ŔFMicrosoft Word Document MSWordDocWord.Document.8ô9˛q